[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573331":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":20,"responsibleParty":32,"collaborators":20,"id":34,"slug":20,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":20,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":20,"enrollmentInfo":42,"targetDuration":20,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":20,"overallStatus":51,"whyStopped":20,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":20},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Maintenance Therapy","EXPERIMENTAL","Patients were treated by Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy",[13],"Drug: Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy","Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","+861066947194","qlr2007@126.com",{"name":31,"role":27,"phone":20,"phoneExt":20,"email":20},"Liren Qian",{"type":24,"investigatorFullName":31,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Associate Chief Physician, Associate Professor","100573331",false,"NCT06744894","SIL as Maintenance Therapy in Multiple Myeloma","Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma","Inclusion Criteria:\n\n* Pathologically confirmed Multiple Myeloma according World Health Organization (WHO) classification;\n* Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).\n* Patient must understand and voluntarily sign an ICF prior to any study-specific assessments\u002Fprocedures being conducted;\n* Patient is willing and able to adhere to the study visit schedule and other protocol requirements;\n* Documented response to ASCT (PR, VGPR, CR\u002Fstringent complete response \\[sCR\\]) according to IMWG criteria.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women","ALL","14 Years",{"count":43,"type":44},50,"ESTIMATED","INTERVENTIONAL",[47],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.",[50],"Multiple Myeloma","NOT_YET_RECRUITING","2024-12-17",{"date":54,"type":55},"2024-12-20","ACTUAL",{"date":57,"type":44},"2025-01-01",{"date":59,"type":44},"2030-01-01",{"name":5,"class":6}]